Table 3.

Risk of the 10 most common adverse event types in patients with CTD-associated PAH compared to patients with idiopathic PAH^*

Outcome	Odds ratio (95% CI) for CTD-associated PAH vs. idiopathic PAH	P
Infection	1.65 (1.31–2.08)	<0.001
Headache	0.85 (0.65–1.13)	0.26
Musculoskeletal	1.13 (0.87–1.48)	0.36
Edema	1.12 (0.85–1.48)	0.42
Rash	0.89 (0.62–1.29)	0.54
Bleeding	1.49 (1.08–2.06)	0.021
Nausea/vomiting	1.10 (0.78–1.54)	0.59
Dizziness	1.09 (0.78–1.52)	0.62
Cough	0.99 (0.66–1.49)	0.98
Dyspnea	1.33 (0.91–1.93)	0.14

^*Odds ratios with 95% confidence intervals (95% CIs) were determined in analyses adjusted for age, sex, race, treatment (drug versus placebo), study, body mass index, baseline 6-minute walk distance, baseline World Health Organization functional class, baseline hemodynamics (cardiac index, mean pulmonary arterial pressure, right atrial pressure), and baseline laboratory values (creatinine and hemoglobin levels). CTD-associated PAH = connective tissue disease–associated pulmonary arterial hypertension.